시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
면역 체크 포인트 저해제 시장 분석과 예측 : 유형, 제품, 용도, 최종 사용자, 기술, 서비스, 성분, 프로세스, 장치(-2034년)
Immune Checkpoint Inhibitor Market Analysis and Forecast to 2034: Type, Product, Application, End User, Technology, Services, Component, Process, Device
상품코드 : 1740680
리서치사 : Global Insight Services LLC
발행일 : 2025년 06월
페이지 정보 : 영문 400 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,750 ￦ 6,587,000
Single User License help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능하며, 인쇄는 가능합니다.
US $ 5,750 ￦ 7,974,000
Site License help
PDF, Excel 보고서를 동일 기업(국가)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,750 ￦ 9,360,000
Enterprise License help
PDF, Excel 보고서를 동일 기업의 전 세계 모든분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


한글목차

면역 체크 포인트 저해제 시장은 2024년 445억 달러로 평가되었고, 2034년에는 1,978억 달러에 이르고, 약 16.1%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측되고 있습니다. PD-1, PD-L1, CTLA-4등의 체크포인트를 표적으로 하고, 다양한 암에 지속적인 반응을 가져오는 것으로 종양학에 혁명을 가져오고 있습니다.

시장 개요 :

면역 체크 포인트 저해제 시장은 암 면역요법의 진보와 세계의 암 이환율의 상승에 힘입어 견고한 확대를 계속하고 있습니다. PD-1/PD-L1 억제제 부문은 흑색종 및 비소세포폐암을 포함한 다양한 악성 종양 치료에 대한 확립된 효능 덕분에 시장을 선도하고 있습니다. 이 부문의 이점은 강력한 임상 증거와 FDA의 승인으로 강화되었으며 치료 요법의 요점이되었습니다. CTLA-4 억제제는 적용 범위가 좁고 독성 프로필이 높아 다른 치료법에 비해 뒤쳐집니다. LAG-3 억제제나 TIGIT 억제제와 같은 새로운 하위 부문은 기존 치료에 대한 내성을 극복해, 치료의 선택지를 넓히는 것이 기대되어, 주목을 모으고 있습니다. 이러한 새로운 체크포인트는 충족되지 않은 요구 사항을 해결하고 병용 요법 전략을 강화하여 시장에 영향을 미칠 준비가 되어 있습니다.

시장 세분화
유형 단일클론항체, 저분자 화합물
제품 PD-1 억제제, PD-L1 억제제, CTLA-4 억제제, LAG-3 억제제
용도 암,자가 면역 질환, 감염
최종 사용자 병원, 클리닉, 외래수술센터(ASC), 연구 기관, 제약 기업
기술 재조합 DNA 기술, 하이 브리 도마 기술
서비스 임상시험, 의약품 개발, 약사 컨설팅
성분 원약, 부형제
프로세스 바이오프로세싱, 제형, 패키징
장치 주입 펌프, 인젝터

주요 동향과 촉진요인

면역 체크 포인트 저해제 시장은 암면역요법의 진보와 암 이환율 증가에 힘입어 강력한 성장을 이루고 있습니다. 제약 회사들은 차세대 억제제를 발견하고 혁신과 경쟁력 있는 차별화를 촉진하기 위해 연구 개발에 많은 투자를 하고 있습니다. 또, 바이오 테크놀로지 기업과 학술기관과의 공동 연구나 제휴가 확대되어, 지식 교환이 촉진되어 임상시험이 가속하고 있는 것도 시장을 뒷받침하고 있습니다. 인공지능과 머신러닝의 통합은 연구 노력을 최적화하고, 시장 투입까지의 시간을 단축해, 정밀의료의 어프로치를 개선하고 있습니다. 다른 혜택으로, 병용 요법은 치료 효과를 높이고 단독 요법과 관련된 내성 문제를 해결하기 위해 새로운 성장의 길이 열리고 있습니다.

주요 억제요인과 도전

면역 체크 포인트 저해제 시장은 현재 몇 가지 중요한 시장 성장 억제요인과 과제를 안고 있습니다. 또한, 새로운 치료 승인을 받는 데는 시간과 비용이 들기 때문에 복잡한 규제 상황이 장애물이 되고 있습니다. 연구가 필요하기 때문에 시장 진입이 지연 될 수 있습니다. 또한 경쟁 구도이 치열 해지고 많은 기업이 시장 점유율을 겨루고 있기 때문에 가격 압력과 이익률의 저하로 이어졌습니다. 병용 요법의 필요성은 치료 요법에 복잡성을 가져오고 임상 관리와 약사 승인 과정을 모두 복잡하게 합니다.

목차

제1장 면역 체크 포인트 저해제 시장 개요

제2장 주요 요약

제3장 시장에 관한 중요 인사이트

제4장 면역 체크 포인트 저해제 시장 전망

제5장 면역 체크 포인트 저해제 시장의 전략

제6장 면역 체크 포인트 저해제 시장 규모

제7장 면역 체크 포인트 저해제 시장 : 유형별

제8장 면역 체크 포인트 저해제 시장 : 제품별

제9장 면역 체크 포인트 저해제 시장 : 용도별

제10장 면역 체크 포인트 저해제 시장 : 최종 사용자별

제11장 면역 체크 포인트 저해제 시장 : 기술별

제12장 면역 체크 포인트 저해제 시장 : 서비스별

제13장 면역 체크 포인트 저해제 시장 :성분별

제14장 면역 체크 포인트 저해제 시장 : 프로세스별

제15장 면역 체크 포인트 저해제 시장 : 장치별

제16장 면역 체크 포인트 저해제 시장 :지역별

제17장 경쟁 구도

제18장 기업 프로파일

SHW
영문 목차

영문목차

Immune Checkpoint Inhibitor Market is anticipated to expand from $44.5 billion in 2024 to $197.8 billion by 2034, growing at a CAGR of approximately 16.1%. The market encompasses therapies designed to block proteins that inhibit immune responses, enhancing the body's ability to fight cancer. These inhibitors target checkpoints like PD-1, PD-L1, and CTLA-4, revolutionizing oncology by offering durable responses in various cancers. The market is driven by rising cancer incidence, advancements in biotechnology, and increasing approvals of novel inhibitors. Ongoing research and strategic collaborations are fostering growth, with a focus on expanding indications and improving patient outcomes.

Market Overview:

The Immune Checkpoint Inhibitor Market is experiencing robust expansion, propelled by advancements in cancer immunotherapy and increasing prevalence of cancer worldwide. The PD-1/PD-L1 inhibitors segment leads the market, attributed to its established efficacy in treating various malignancies, including melanoma and non-small cell lung cancer. This segment's dominance is reinforced by strong clinical evidence and FDA approvals, making it a cornerstone of treatment regimens. CTLA-4 inhibitors, while significant, trail due to narrower applications and higher toxicity profiles. Emerging sub-segments, such as LAG-3 and TIGIT inhibitors, are gaining attention as they hold promise in overcoming resistance to existing therapies and expanding treatment options. These novel checkpoints are poised to impact the market by addressing unmet needs and enhancing combination therapy strategies. The continuous innovation and strategic collaborations within the pharmaceutical industry are expected to drive further growth and diversification of the immune checkpoint inhibitor landscape.

Market Segmentation
TypeMonoclonal Antibodies, Small Molecules
ProductPD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors, LAG-3 Inhibitors
ApplicationOncology, Autoimmune Diseases, Infectious Diseases
End UserHospitals, Clinics, Ambulatory Surgical Centers, Research Institutes, Pharmaceutical Companies
TechnologyRecombinant DNA Technology, Hybridoma Technology
ServicesClinical Trials, Drug Development, Regulatory Consulting
ComponentActive Pharmaceutical Ingredients, Excipients
ProcessBioprocessing, Formulation, Packaging
DeviceInfusion Pumps, Injectors

Geographical Overview:

The Immune Checkpoint Inhibitor Market is witnessing robust growth across various regions, each exhibiting unique characteristics. North America dominates the market, driven by advanced healthcare infrastructure and significant investments in cancer research. The region's focus on innovative therapies and strong regulatory support further propels market expansion. Europe follows closely, with its mature healthcare systems and substantial funding for oncology research. The emphasis on personalized medicine and targeted therapies enhances the market's growth prospects. In the Asia Pacific region, the market is expanding rapidly due to increasing cancer prevalence and rising healthcare expenditures. Governments are investing heavily in healthcare infrastructure and research, fostering a conducive environment for market growth. Latin America presents emerging opportunities, with a growing focus on improving cancer care and increasing access to advanced therapies. The Middle East & Africa are gradually recognizing the potential of immune checkpoint inhibitors in addressing the region's cancer burden. These regions are witnessing increased collaborations between local governments, healthcare providers, and pharmaceutical companies to enhance access and affordability. The global market is poised for significant advancements as more regions adopt these innovative therapies. Such developments are expected to lead to improved patient outcomes and a broader reach for immune checkpoint inhibitors worldwide.

Recent Developments:

The Immune Checkpoint Inhibitor Market has experienced notable developments over the past three months. Roche has announced a strategic partnership with BioNTech to co-develop a novel checkpoint inhibitor, aiming to enhance efficacy in oncology treatments. Merck has expanded its collaboration with Moderna, focusing on combining checkpoint inhibitors with mRNA technology to target various cancer types. AstraZeneca has successfully launched a new checkpoint inhibitor in Japan, receiving regulatory approval for its use in treating advanced lung cancer, marking a significant milestone in the region. Bristol Myers Squibb has reported a substantial increase in sales of its flagship checkpoint inhibitor, attributed to expanded indications and successful market penetration in emerging economies. Furthermore, a significant merger between two mid-sized biotech firms, Innoviva and La Jolla Pharmaceutical, has been announced, with a focus on accelerating the development of next-generation checkpoint inhibitors. These developments underscore the dynamic nature of the immune checkpoint inhibitor market, highlighting significant collaborations, product launches, and financial growth.

Key Companies:

Bei Gene, Innovent Biologics, Junshi Biosciences, CStone Pharmaceuticals, Hengrui Medicine, Chipscreen Biosciences, Zai Lab, I- Mab Biopharma, Harbour Bio Med, Akeso Biopharma, Alphamab Oncology, Tiziana Life Sciences, Medivir, Oncolys Bio Pharma, Immunocore, Agenus, Compugen, Macro Genics, Pieris Pharmaceuticals, Onco Sec Medical

Key Trends and Drivers:

The Immune Checkpoint Inhibitor Market is experiencing robust growth, fueled by advancements in cancer immunotherapy and increasing cancer prevalence. Key trends include the development of novel checkpoint inhibitors targeting new pathways, enhancing treatment efficacy and patient outcomes. Pharmaceutical companies are investing heavily in research and development to discover next-generation inhibitors, driving innovation and competitive differentiation. The market is also propelled by growing collaborations and partnerships between biotech firms and academic institutions, facilitating knowledge exchange and accelerating clinical trials. Regulatory approvals for new therapies are expanding treatment options, contributing to market expansion. Furthermore, the integration of artificial intelligence and machine learning in drug discovery processes is optimizing research efforts, reducing time to market, and improving precision medicine approaches. Opportunities abound in emerging markets where healthcare infrastructure is improving, and cancer awareness is rising. Companies focusing on affordable and accessible therapies are well-positioned to capture market share. Additionally, the increasing use of combination therapies is opening new avenues for growth, as they offer enhanced therapeutic benefits and address resistance issues associated with monotherapies. The market's potential is further amplified by personalized medicine trends, tailoring treatments to individual patient profiles for improved efficacy and safety.

Key Restraints and Challenges:

The Immune Checkpoint Inhibitor Market is currently navigating several significant restraints and challenges. Firstly, the prohibitive cost of these therapies limits their accessibility, particularly in low-income regions, curtailing market expansion. Additionally, the complex regulatory landscape poses a hurdle, as obtaining approval for new treatments is both time-consuming and costly. Adverse effects associated with immune checkpoint inhibitors, such as autoimmune reactions, raise safety concerns and necessitate further research, which can delay market entry. Furthermore, the competitive landscape is intensifying, with numerous companies vying for market share, leading to pricing pressures and reduced profit margins. Lastly, the need for combination therapies to enhance efficacy introduces complexity in treatment regimens, complicating both clinical management and regulatory approval processes. These challenges collectively impede the rapid growth and broader adoption of immune checkpoint inhibitors.

Sources:

U.S. Food and Drug Administration - Center for Drug Evaluation and Research, National Institutes of Health - National Cancer Institute, European Medicines Agency, World Health Organization - International Agency for Research on Cancer, American Association for Cancer Research, Society for Immunotherapy of Cancer, European Society for Medical Oncology, American Society of Clinical Oncology, International Union Against Cancer, Cancer Research UK, National Comprehensive Cancer Network, Japan Society of Clinical Oncology, German Cancer Research Center, European Cancer Organisation, International Conference on Immunotherapy in Cancer, World Cancer Congress, Keystone Symposia on Molecular and Cellular Biology - Cancer Immunotherapy, Cold Spring Harbor Laboratory Meetings - Cancer Immunotherapy, AACR Annual Meeting, ESMO Congress

Research Scope:

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1: Immune Checkpoint Inhibitor Market Overview

2: Executive Summary

3: Premium Insights on the Market

4: Immune Checkpoint Inhibitor Market Outlook

5: Immune Checkpoint Inhibitor Market Strategy

6: Immune Checkpoint Inhibitor Market Size

7: Immune Checkpoint Inhibitor Market, by Type

8: Immune Checkpoint Inhibitor Market, by Product

9: Immune Checkpoint Inhibitor Market, by Application

10: Immune Checkpoint Inhibitor Market, by End User

11: Immune Checkpoint Inhibitor Market, by Technology

12: Immune Checkpoint Inhibitor Market, by Services

13: Immune Checkpoint Inhibitor Market, by Component

14: Immune Checkpoint Inhibitor Market, by Process

15: Immune Checkpoint Inhibitor Market, by Device

16: Immune Checkpoint Inhibitor Market, by Region

17: Competitive Landscape

18: Company Profiles

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기